<SEC-DOCUMENT>0001193125-24-081580.txt : 20240329
<SEC-HEADER>0001193125-24-081580.hdr.sgml : 20240329
<ACCEPTANCE-DATETIME>20240329083203
ACCESSION NUMBER:		0001193125-24-081580
CONFORMED SUBMISSION TYPE:	424B5
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20240329
DATE AS OF CHANGE:		20240329

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CalciMedica, Inc.
		CENTRAL INDEX KEY:			0001534133
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				452120079
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		424B5
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-273949
		FILM NUMBER:		24802119

	BUSINESS ADDRESS:	
		STREET 1:		505 COAST BOULEVARD SOUTH
		STREET 2:		SUITE 307
		CITY:			LA JOLLA
		STATE:			CA
		ZIP:			92037
		BUSINESS PHONE:		858-952-5500

	MAIL ADDRESS:	
		STREET 1:		505 COAST BOULEVARD SOUTH
		STREET 2:		SUITE 307
		CITY:			LA JOLLA
		STATE:			CA
		ZIP:			92037

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CalciMedica, Inc. /DE/
		DATE OF NAME CHANGE:	20230322

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	GRAYBUG VISION, INC.
		DATE OF NAME CHANGE:	20170717

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	GRAYBUG, Inc.
		DATE OF NAME CHANGE:	20150303
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B5
<SEQUENCE>1
<FILENAME>d781527d424b5.htm
<DESCRIPTION>424B5
<TEXT>
<HTML><HEAD>
<TITLE>424B5</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Filed Pursuant to Rule 424(b)(5) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Registration <FONT STYLE="white-space:nowrap">No.&nbsp;333-273949</FONT> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>PROSPECTUS SUPPLEMENT </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(To Prospectus dated
August&nbsp;18, 2023) </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g781527g0328205406757.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Up to $17,068,386 of Shares of </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Common Stock </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus
supplement amends our prospectus dated August&nbsp;18, 2023 (the &#147;Prior Prospectus&#148;), filed as part of our registration statement on Form <FONT STYLE="white-space:nowrap">S-3</FONT> (File
<FONT STYLE="white-space:nowrap">No.&nbsp;333-273949).</FONT> This prospectus supplement should be read in conjunction with the Prior Prospectus, and is qualified by reference thereto, except to the extent that the information herein amends or
supersedes the information contained in the Prior Prospectus. This prospectus supplement is not complete without, and may only be delivered or utilized in connection with, the Prior Prospectus, and any future amendments or supplements thereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We filed the Prior Prospectus to register the offer and sale of our common stock, par value $0.0001 per share, from time to time pursuant to
the terms of that certain at the market offering agreement (the &#147;Offering Agreement&#148;), between H.C. Wainwright&nbsp;&amp; Co., LLC (&#147;Wainwright&#148;), acting as sales agent, and us. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are filing this prospectus supplement to amend the Prior Prospectus to update the amount of shares we are eligible to sell under General
Instruction I.B.6 on Form <FONT STYLE="white-space:nowrap">S-3.</FONT> As a result of these limitations and the current public float of our common stock, and in accordance with the terms of the Offering Agreement, we may offer and sell shares of our
common stock having an aggregate offering price of up to $17,068,386 from time to time through Wainwright, as further described below. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As
of the date of this prospectus supplement, the aggregate market value of our common stock held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> of our public float was $52,044,474 based on a total number of 10,740,115 shares of common stock
outstanding, of which 6,995,225 shares of common stock were held by <FONT STYLE="white-space:nowrap">non-affiliates,</FONT> at a price of $7.44 per share, the closing sales price of our common stock on January&nbsp;31, 2024, which is the highest
closing price of our common stock on the Nasdaq Capital Market within the prior 60 days. We have sold $279,771.74 of securities pursuant to General Instruction I.B.6 of Form <FONT STYLE="white-space:nowrap">S-3</FONT> during the prior <FONT
STYLE="white-space:nowrap">12-calendar</FONT> month period that ends on and includes the date of this prospectus supplement (excluding this offering). Accordingly, based on the foregoing, we are currently eligible under General Instruction I.B.6 of
Form <FONT STYLE="white-space:nowrap">S-3</FONT> to offer and sell shares of our common stock having an aggregate offering price of up to $17,068,386. Pursuant to General Instruction I.B.6 of Form <FONT STYLE="white-space:nowrap">S-3,</FONT> in no
event will we sell securities in a public primary offering with a value exceeding <FONT STYLE="white-space:nowrap">one-third</FONT> of our public float in any <FONT STYLE="white-space:nowrap">12-month</FONT> period so long as our public float
remains below $75.0&nbsp;million. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our common stock is listed on the Nasdaq Capital Market under the trading symbol &#147;CALC.&#148; On
March&nbsp;28, 2024, the last reported sale price of our common stock was $4.16&nbsp;per share. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Neither the Securities and Exchange
Commission nor any state securities commission has approved or disapproved of these securities or determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense. </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman" ALIGN="center"><B>H.C. Wainwright&nbsp;&amp; Co. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>The date of this prospectus supplement is March&nbsp;29, 2024. </B></P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g781527g0328205406757.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g781527g0328205406757.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !  4,# 2(  A$! Q$!_\0
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F,4M% "8%&!2T4 )@48%+10 F!1@4M% "8HP*6B@!,"BEHH __]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
